Analgesic use and sex steroid hormone concentrations in postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 4, 2010, Pages 1033-1041

  Gates, Margaret A ^a,c   Tworoger, Shelley S ^a,c   Heather Eliassen, A ^a   Missmer, Stacey A ^a,b,c   Hankinson, Susan E ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SEX HORMONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; RADIOIMMUNOASSAY; RISK FACTORS;

EID: 77950822801     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0975     Document Type: Article

References (53)

1. 1. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. BrJ Cancer 2001;84:1188-1192 (Pubitemid 32511336)
2. 2. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003;3:28. (Pubitemid 38851321)
3. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemlol Drug Saf 2008;17: 115-124
4. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008;100:1439-1447
5. Eliassen AH, Chen WY, Spiegelman D, Wille WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-Inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses' Health Study II. Arch Intern Med 2009; 169:115-21.
6. Zhao YS, Zhu S, LI XW, et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 2009;117:141-150
7. Fairfield KM, Hunter DJ, Fuchs CS, Colditz GA, Hankinson SE. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002;13:535-542
8. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2000;9:933-937
9. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology 2006;17:104-107
10. 10. Wernll KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer 2008;98:1781-1783 (Pubitemid 351748854)
11. 11. Bonovas S, Filloussl K, Sitaras NM. Paracetamol use and risk of ovarian cancer: a meta-analysis. Br J Clin Pharmacol 2006;62: 113-121 (Pubitemid 44195247)
12. 12. Bonovas S, Filioussl K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 2005;60:194-203. (Pubitemid 41075905)
13. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 2006; 17: 871-888
14. Moysich KB, Beehler GP, Zirpoli G, Choi JY, Baker JA. Use of common medications and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 1564-1595
15. Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL. Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 2008; 167: 1430-1437
16. Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE. Use of nonsteroidal antilnflammatory agents and incidence of ovarian cancer In 2 large prospective cohorts. Am J Epidemiol 2009; 169: 1378-1387
17. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006;6:221-232
18. 18. Brueggemeier RW, Qulnn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140:27-35. (Pubitemid 29251310)
19. Graham GG, Scott KF. Mechanism of action of paracetamol. Am J Ther 2005;12:46-55.
20. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sei USA 2002;99:7130-7135
21. 21. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008;22: 383-390 (Pubitemid 351225574)
22. 22. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998;351:104-107 (Pubitemid 28026637)
23. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297-302.
24. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96: 1856-1865
25. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: Does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006; 24: 1823-1830
26. 26.HankinsonSE,WillettWC,MichaudDS,etal. Plasmaprolactinlevelsandsubsequentriskofbreastcancerinpostmenopausalwomen. JNatlCancerInst1999;91:629-634(Pubitemid29194050)
27. 27.HankinsonSE,WillettWC,MansonJE,etal. PlasmasexsteroidhormonelevelsandriskofbreastcancerInpostmenopausalwomen. JNatlCancerInst1998;90:1292-1299(Pubitemid28433474)
28. 28. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 ß to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801-810 (Pubitemid 13228095)
29. 29.RosnerB.PercentagepointsforageneralizedESDmany-outlierprocedure. Technometrlcs1983;25:165-172(Pubitemid13540616)
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
31. 31.McTiernanA,WuL,ChenC,etal.RelationofBMIandphysicalactivity- sexhormonesInpostmenopausalwomen.Obesity(SilverSpring)2006;14: 1662-1677(Pubitemid46214834)
32. 32. McTiernan A, Wu L, Barnabei VM, et al. Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels In postmenopausal women. Breast Cancer Res Treat 2008; 108: 217-231 (Pubitemid 351311354)
33. 33. Hudson AG, Glerach GL, Modugno F, et al. Nonsteroidal antiinflammatory drug use and serum total estradiol In postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:680-687 (Pubitemid 351469220)
34. 34. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137: 5739-5742 (Pubitemid 26423150)
35. Miller WL, Styne DM. Female puberty and its disorders. In: Yen SSC, Jaffa RB, Barbierl RL, editors. Reproductive Endocrinology. 4th ed Philadelphia: W.B. Saunders Company; 1999, p. 388-412.
36. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis 2005;24:3-15.
37. Ellassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol 2008;630:148-165
38. Kotsopoulos J, Vitonls AF, Terry KL, et al. Coffee Intake, variants In genes involved in caffeine metabolism, and the risk of epithelial ovarian cancer. Cancer Causes Control 2009;20:335-44.
39. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005; 14: 98-107.
40. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45-53.
41. 41. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Coldltz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007; 96: 151-156 (Pubitemid 46094654)
42. 42. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005; 26: 331-345 (Pubitemid 40686647)
43. 43. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-2440 (Pubitemid 38669186)
44. 44. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-812 (Pubitemid 40909123)
45. Gierach GL, Lacey JV, Jr., Schatzkln A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008;10:R38.
46. 46. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the CaseControl Surveillance Study revisited. Am J Epidemiol 2005;162:165-170 (Pubitemid 41373542)
47. 47. Galllcchlo L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-Inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 2007; 121: 211-215 (Pubitemid 46753870)
48. 48. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 2007; 166: 1150-1158 (Pubitemid 350022753)
49. 49. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 2007; 166: 709-716 (Pubitemid 47347905)
50. 50. Friis S, Thomassen L, Sorensen HT, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008; 17: 88-96. (Pubitemid 351301619)
51. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarkers Prev 1995; 4: 649-654
52. 52. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline In renal function in women. Arch Intern Med 2004; 164: 1519-1524 (Pubitemid 38970471)
53. Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 3116-3122